远程医疗公司Hims & Hers Health Inc.（股票代码：HIMS）今日盘中股价大幅上涨5.16%，引起了市场的广泛关注。
消息面上，公司近期宣布了两项重要进展。首先，Hims & Hers Health已与制药巨头诺和诺德（NVO.US）达成新的合作伙伴关系，将在其平台上销售诺和诺德的王牌品牌减肥药Ozempic和Wegovy，其中包括备受欢迎的Wegovy口服片剂。同时，诺和诺德同意撤回此前对Hims & Hers Health提起的诉讼，标志着双方持续数月的法律争执得到解决。作为协议的一部分，Hims & Hers Health将不再为其仿制版诺和诺德药物投放广告。
其次，公司为推进战略转型，已聘请曾在礼来（LLY.US）负责公司传播事务长达五年的资深公关人士凯瑟琳·贝瑟（Kathryn Beiser）担任首席传播官。首席执行官安德鲁·杜杜姆表示，在当前关键时刻，贝瑟正是公司所需的传播领导者。这些举措被视为公司从销售仿制药转向专注于提供品牌药物战略转型的重要一步，增强了市场对其在快速增长减肥药市场前景的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.